|1.||Goldberg, Richard M: 3 articles (05/2013 - 06/2005)|
|2.||Niedzwiecki, Donna: 2 articles (05/2013 - 08/2011)|
|3.||Bertagnolli, Monica M: 2 articles (05/2013 - 08/2011)|
|4.||Warren, Robert S: 2 articles (05/2013 - 08/2011)|
|5.||Mellstedt, Håkan: 2 articles (12/2010 - 07/2003)|
|6.||Liljefors, Maria: 2 articles (12/2010 - 07/2003)|
|7.||Kufer, Peter: 2 articles (01/2010 - 07/2002)|
|8.||Riethmüller, Gert: 2 articles (01/2010 - 07/2002)|
|9.||Raum, Tobias: 2 articles (01/2010 - 07/2002)|
|10.||Baeuerle, Patrick A: 2 articles (01/2010 - 07/2002)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
02/01/2001 - "An initial study of 189 patients with resected stage III colorectal cancer showed that edrecolomab reduced the relative risk of mortality by 32% compared with observation alone (P < .01). "
02/01/2001 - "Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer."
10/01/2000 - "Encouraging results of several clinical trials were recently reported using edrecolomab for adjuvant therapy after surgery of Duke's C colorectal cancer. "
04/01/1994 - "MAb 17-1A has been used in many therapeutic trials as an immunotherapeutic agent to combat advanced colorectal cancer, and about 5-10% overall responses have been observed. "
03/01/1994 - "In this study induction of an immune network cascade in ten patients with colorectal carcinoma, treated with mAb 17-1A (ab1) was assessed. "
01/01/1991 - "We report the results of clinical trials of the monoclonal antibody (Mab) 17-1A in patients with histologically verified unresectable pancreatic exocrine cancer. "
06/01/2005 - "From January 1997 until July 2000 a total of 377 patients were postoperatively stratified according to tumor stage (T3 vs. T4) and center, and randomly allocated to either treatment with edrecolomab (cohort A, n = 183) or observation (cohort B, n = 194). "
11/01/2003 - "Three hours following the injection of tumor cells into the peritoneal cavity, mAb 17-1A alone and in combination with human LAK cells were given intraperitoneally at different dosages. "
08/15/2000 - "Patients with 17-1A-positive tumors might benefit from an adjuvant therapy with MAb 17-1A after completely resected NSCLC."
02/01/1996 - "Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A."
07/01/1996 - "Therefore, treatment of minimal residual disease with high-affinity mAb 323/ A3 is expected to improve the clinical results obtained with mAb 17-1A."
07/01/1995 - "The first proof of efficacy of a monoclonal antibody in minimal residual disease has recently been published, with mAb 17-1A in patients with colorectal cancer stage III after complete resection of the primary tumour. "
10/01/1998 - "Adjuvant therapy with edrecolomab (500 mg initial dose followed by four 100 mg infusions administered at 4-weekly intervals) significantly improved survival and reduced the tumour recurrence rate in patients with resected Dukes' stage C colorectal cancer and minimal residual disease. "
10/01/1999 - "Indeed, adjuvant treatment with mAb 17-1A did successfully reduce the 5 years mortality among colorectal cancer patients with minimal residual disease. "
10/01/1995 - "These results suggest that high affinity mAbs like 323/A3 might dramatically improve the clinical results obtained thus far with the low affinity mAb 17-1A in the adjuvant treatment of surgically resected Dukes C colorectal cancer patients with minimal residual disease."
|4.||Colonic Neoplasms (Colon Cancer)
07/01/2003 - "While phase III trials of edrecolomab have not demonstrated improved efficacy as adjuvant therapy for stage III colon cancer, newer agents with improved affinity, less chimerism, and improved delivery may still demonstrate benefit."
08/10/2011 - "We conducted a randomized trial comparing adjuvant treatment with edrecolomab versus observation in patients with resected, low-risk, stage II colon cancer. "
04/20/2009 - "When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab."
06/01/2005 - "In the present study, postoperative adjuvant treatment with edrecolomab in patients with resected stage II colon cancer did not improve overall or disease-free survival."
06/01/2005 - "Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study."
07/01/2002 - "The fully human nature and the improved ADCC of MT201 with human effector cells will make MT201 a promising candidate for the clinical development of a novel pan-carcinoma antibody that is superior to edrecolomab."
04/01/1994 - "In our immunohistological studies different reaction patterns of these two MAbs were observed, suggesting that MAb 323/A3 reacts more intensely with carcinoma cells than MAb 17-1A. "
07/01/1986 - "Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results."
02/01/1993 - "Twenty-eight patients with unresectable, measurable pancreatic carcinoma and Eastern Oncology Cooperative Group (ECOG) performance status of 0 or 1 were treated with the murine monoclonal antibody 17-1A, planning to administer 500 mg i.v. three times weekly for 8 weeks. "
02/01/1993 - "Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma."
|1.||monoclonal antibody 17-1A (Edrecolomab)
|3.||Interferon-gamma (Interferon, gamma)
|4.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|5.||tumor-associated antigen GA733
|6.||Interferon-alpha (Interferon Alfa)
|8.||Macrophage Colony-Stimulating Factor
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)